News | July 06, 2022
Regeneron completes purchase of Sanofi's stake in Libtayo
Company provides anticipated impact to second quarter 2022 financial results due to recently completed business development transactions
Company provides anticipated impact to second quarter 2022 financial results due to recently completed business development transactions
Younger Indians have a 10 times higher rate of heart attack
Safety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indications1,2
First and only PARP inhibitor to improve invasive disease-free survival in patients
This new €59 million, 70,000 square foot facility, officially opened today, brings 50 new jobs to the area
Acceptance based on results from the phase 3 KEYNOTE-091 trial
TAK-003 is currently undergoing regulatory review for potential licensure in both the European Union
Scemblix (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif (bosutinib) at 96 weeks
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
This Keytruda combination is the first immunotherapy option approved in the EU for high-risk early-stage TNBC
Subscribe To Our Newsletter & Stay Updated
